Stay updated on OP-1250 vs Standard in ER+/HER2- Advanced Breast Cancer Clinical Trial
Sign up to get notified when there's something new on the OP-1250 vs Standard in ER+/HER2- Advanced Breast Cancer Clinical Trial page.

Latest updates to the OP-1250 vs Standard in ER+/HER2- Advanced Breast Cancer Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoNo Change Detected
- Check20 days agoChange DetectedNew operating-status notice and version update to v3.2.0; previous v3.1.0 version tag removed.SummaryDifference2%

- Check27 days agoChange DetectedUpdated version to v3.1.0 and added contact phone number 415-651-7206.SummaryDifference0.1%

- Check42 days agoChange DetectedRevision updated from v3.0.1 to v3.0.2; the 'Back to Top' link was removed.SummaryDifference0.1%

- Check49 days agoChange DetectedThe page has been updated to reflect a new version, v3.0.1, indicating a recent revision. The previous version, v3.0.0, has been removed from the page.SummaryDifference0.2%

- Check56 days agoChange DetectedThe webpage has been updated to include new clinical trial locations across various countries, including the addition of specific sites in the UK, Spain, South Korea, Canada, and Argentina. Additionally, the drug information section has been expanded to include details about Fulvestrant, Anastrozole, Letrozole, and Exemestane.SummaryDifference34%

- Check70 days agoChange DetectedThe web page has been updated from version 2.16.11 to version 2.16.12.SummaryDifference0.1%

Stay in the know with updates to OP-1250 vs Standard in ER+/HER2- Advanced Breast Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the OP-1250 vs Standard in ER+/HER2- Advanced Breast Cancer Clinical Trial page.